The C2N AD pathology test uses APOE variant, the ratio of amyloid beta 42 to 40 in plasma, and patient age to predict Alzheimer's disease pathology.

“the c2n developed amyloid score uses a couple of things it uses a patient's apoe uh variant so it sort of says is this patient uh you know a three three a three four four four Etc and then it looks at the ratio of um two variants of amyloid beta so amyloid beta 42 and amyloid beta 40. and then also looks at their age okay so it takes apoe status uh AB 40 to 42 ratio as measured in the plasma and patient age and then it predicts the probability of AD pathology”